Nkarta, Inc. NKTX
1.35 USD -0.14 (-9.12%)
Nov 12, 2026, 1:26 PM EST
1.33 Day range 1.43
1.13 52-week range 3.72
- YTD
- -27.30%
- 1 year
- -31.38%
News
benzinga.com Nkarta Announces Clean Safety Profile for Cell Therapy Across Five Autoimmune Indications Nkarta (NKTX) reports positive Phase 1/2 safety data for NKX019 cell therapy with zero severe immune toxicities across 5 autoimmune diseases.
benzinga.com Nkarta Announces Integrated Safety Results From 40 Patients Treated With NKX019, Allogeneic, Off-The-Shelf, CD19-Directed CAR NK Cell Therapy Candidate In Ongoing Ntrust Clinical Trial Program No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS),…
globenewswire.com Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026 No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS),…
seekingalpha.com Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript Nkarta, Inc. ( NKTX ) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis November 9, 2026 8:00 AM EST Company Participants Paul Hastings - CEO & Director Shawn Rose - Chief…
benzinga.com Nkarta Reports Initial Clinical Data For NKX019 Demonstrating Early Efficacy And Favorable Tolerability In Autoimmune Disease Trial In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in…
globenewswire.com Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock…
benzinga.com Nkarta To Host Webcast On November 9 To Review Initial Clinical Data From Ntrust Program Evaluating NKX019 In Myositis And Systemic Sclerosis Being Presented At ACR Convergence 2026 Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it will host a webcast…
globenewswire.com Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…- benzinga.com Nkarta Q3 EPS $(0.45) Misses $(0.42) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.42) by 7.14 percent. This is a 55.17 percent decrease over losses of $(0.29) per…
globenewswire.com Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat…
benzinga.com HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12 HC Wainwright & Co. analyst Douglas Tsao assumes Nkarta (NASDAQ:NKTX) with a Buy rating and announces Price Target of $12.- benzinga.com Stifel Maintains Buy on Nkarta, Lowers Price Target to $10 Stifel analyst Stephen Willey maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $11 to $10.
benzinga.com HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14 HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $16 to $14.
benzinga.com Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31)…
benzinga.com Nkarta Q1 EPS $(0.37), Inline Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period…
benzinga.com Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $12 Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price target from $14 to $12.- benzinga.com Nkarta Q4 EPS $(0.37) Misses $(0.34) Estimate Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.34) by 9.79 percent. This is a 5.71 percent decrease over losses of $(0.35) per…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
- benzinga.com Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
benzinga.com Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode…
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
- benzinga.com Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 112 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 109 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 43 companies set new 52-week lows.
- benzinga.com Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 100 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 135 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday OnWednesday, 78 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday's session saw 329 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 297 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's trading, 293 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 241 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday saw 196 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's trading, 138 companies set new 52-week lows.
- benzinga.com Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares Slide U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 points on Monday.